OAKTREE ACQUISITION CORP. II

(OACB)
  Report
Delayed Nyse  -  05/20 03:59:16 pm EDT
9.950 USD   -0.05%
05/16Oaktree Acquisition Corp. II Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/16Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®
BU
05/11Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business Combination
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
9.94(c) 9.94(c) 9.945(c) 9.955(c) 9.95(c) Last
41 709 41 379 84 997 151 372 71 572 Volume
0.00% 0.00% +0.05% +0.10% -0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 110 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 219 M - -
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 311 M 311 M -
Capi. / Sales 2022 2,83x
Capi. / Sales 2023 1,42x
Nbr of Employees -
Free-Float 80,0%
More Financials
Company
Oaktree Acquisition Corp. II. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not identified any potential business combination target and has initiated any substantive discussions, directly or indirectly, with any potential... 
Sector
Investment Holding Companies
Calendar
-
More about the company
All news about OAKTREE ACQUISITION CORP. II
05/16Oaktree Acquisition Corp. II Reports Earnings Results for the First Quarter Ended March..
CI
05/16Alvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, ..
BU
05/11Alvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 202..
BU
04/19Alvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on ..
BU
04/18Oaktree Acquisition Corp. II Appoints Alexander Taubman as Class III Director
CI
04/18Oaktree Acquisition Corp. II Announces Executive Changes
CI
04/06OAKTREE ACQUISITION II : Press Release, dated April 6, 2022 - Form 8-K
PU
04/06Alvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concent..
BU
03/30Oaktree Acquisition Corp. II Reports Earnings Results for the Full Year Ended December ..
CI
03/30Oaktree Acquisition Corp. II Auditor Raises 'Going Concern' Doubt
CI
03/21Northland Starts Oaktree Acquisition Corp. II at Outperform With $15 Price Target
MT
03/08OAKTREE ACQUISITION II : Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbV..
PU
03/08Alvotech Resolves U.S. Patent and Trade Secret Disputes with AbbVie, Securing U.S. Righ..
BU
01/18OAKTREE ACQUISITION II : Alvotech Upsizes Oversubscribed PIPE Transaction to Approximately..
PU
01/18Oaktree Acquisition, Alvotech Holdings Complete Upsized $175 Million PIPE Stock Sale
MT
More news
News in other languages on OAKTREE ACQUISITION CORP. II
05/16Oaktree Acquisition Corp. II annonce ses résultats pour le premier trimestre clos le 31..
04/21Alvotech verbetert toegang tot kapitaal en stroomlijnt traject naar verwachte openbare ..
04/20Alvotech améliore son accès aux capitaux et optimise son processus d'entrée en bourse, ..
04/20Alvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-Notierung
04/20Alvotech mejora el acceso al capital y agiliza el proceso hacia la esperada cotización ..
More news
Analyst Recommendations on OAKTREE ACQUISITION CORP. II
More recommendations
Chart OAKTREE ACQUISITION CORP. II
Duration : Period :
Oaktree Acquisition Corp. II Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OAKTREE ACQUISITION CORP. II
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 9,96 $
Average target price 19,00 $
Spread / Average Target 90,9%
Managers and Directors
Alexander A. Taubman President, Chief Executive Officer & Director
Zaid Pardesi Chief Financial Officer, Head-M&A
John B. Frank Chairman
Mathew M. Pendo Chief Operating Officer
Paul M. Meister Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OAKTREE ACQUISITION CORP. II0.76%311
INVESTOR AB (PUBL)-20.58%55 540
CK HUTCHISON HOLDINGS LIMITED10.14%27 072
GROUPE BRUXELLES LAMBERT SA-14.65%12 929
HAL TRUST-7.82%12 338
AB INDUSTRIVÄRDEN (PUBL)-14.29%10 728